1. Home
  2. APLM vs LSH Comparison

APLM vs LSH Comparison

Compare APLM & LSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLM
  • LSH
  • Stock Information
  • Founded
  • APLM 2016
  • LSH 2018
  • Country
  • APLM United States
  • LSH United States
  • Employees
  • APLM N/A
  • LSH N/A
  • Industry
  • APLM Blank Checks
  • LSH
  • Sector
  • APLM Finance
  • LSH
  • Exchange
  • APLM Nasdaq
  • LSH NYSE
  • Market Cap
  • APLM 7.7M
  • LSH 7.3M
  • IPO Year
  • APLM N/A
  • LSH 2024
  • Fundamental
  • Price
  • APLM $6.56
  • LSH $1.03
  • Analyst Decision
  • APLM Strong Buy
  • LSH
  • Analyst Count
  • APLM 1
  • LSH 0
  • Target Price
  • APLM $200.00
  • LSH N/A
  • AVG Volume (30 Days)
  • APLM 57.9K
  • LSH 37.3K
  • Earning Date
  • APLM 04-03-2025
  • LSH 05-01-2025
  • Dividend Yield
  • APLM N/A
  • LSH N/A
  • EPS Growth
  • APLM N/A
  • LSH N/A
  • EPS
  • APLM N/A
  • LSH N/A
  • Revenue
  • APLM $198,000.00
  • LSH $16,927,719.00
  • Revenue This Year
  • APLM $415.15
  • LSH N/A
  • Revenue Next Year
  • APLM N/A
  • LSH N/A
  • P/E Ratio
  • APLM N/A
  • LSH N/A
  • Revenue Growth
  • APLM N/A
  • LSH 2.84
  • 52 Week Low
  • APLM $4.71
  • LSH $0.88
  • 52 Week High
  • APLM $49.00
  • LSH $5.37
  • Technical
  • Relative Strength Index (RSI)
  • APLM 50.05
  • LSH N/A
  • Support Level
  • APLM $5.41
  • LSH N/A
  • Resistance Level
  • APLM $6.19
  • LSH N/A
  • Average True Range (ATR)
  • APLM 0.76
  • LSH 0.00
  • MACD
  • APLM 0.10
  • LSH 0.00
  • Stochastic Oscillator
  • APLM 86.05
  • LSH 0.00

About APLM Apollomics Inc.

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

About LSH LAKESIDE HOLDING LTD

Lakeside Holding Ltd i an integrated cross-border supply chain solution provider with a strategic focus on the Asian market including China and South Korea. It provides customized cross-border ocean freight solutions and airfreight solutions in the U.S, including cross-border freight consolidation and forwarding services; customs clearance services; warehousing and distribution services and U.S. domestic ground transportation services.

Share on Social Networks: